Ptc Therapeutics (PTCT) Intangibles (2017 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Intangibles of $402.9 million for Q2 2026, up 180.19% year-over-year from $143.8 million in Q2 2025, and up 5.84% quarter-over-quarter from $380.7 million in Q1 2026.
Ptc Therapeutics (PTCT) Intangibles (2017 - 2026) Analysis & Trends
Ptc Therapeutics' Intangibles history runs 10 years deep, the most recent figure standing at $402.9 million for Q2 2026.
- In Q2 2026, Intangibles rose 180.19% year-over-year to $402.9 million; the TTM figure through Jun 2026 stood at $402.9 million (up 180.19% YoY), while the FY2025 annual figure was $388.8 million, up 227.25% from the prior year.
- Intangibles for Q2 2026 stood at $402.9 million, up from $380.7 million in the prior quarter.
- The five-year high for Intangibles was $763.7 million in Q1 2022, with the low at $118.4 million in Q1 2025.
- The 5-year median for Intangibles is $392.6 million (2025), against an average of $436.7 million.
- The sharpest annual moves came in 2024 and 2025: Intangibles sank 68.7% in 2024, then jumped 227.25% in 2025.
- Ptc Therapeutics' Intangibles stood at $705.9 million in 2022, then tumbled by 46.24% to $379.5 million in 2023, then tumbled by 68.7% to $118.8 million in 2024, then surged by 227.25% to $388.8 million in 2025, then advanced by 3.65% to $402.9 million in 2026.
- Business Quant data shows PTCT's Intangibles at $402.9 million in Q2 2026, $380.7 million in Q1 2026, and $388.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 402.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 402.93 Mn |
| Mar 31, 2026 | 380.68 Mn |
| Dec 31, 2025 | 388.75 Mn |
| Sep 30, 2025 | 396.47 Mn |
| Jun 30, 2025 | 143.81 Mn |
| Mar 31, 2025 | 118.45 Mn |
| Sep 30, 2024 | 330.37 Mn |
| Jun 30, 2024 | 329.88 Mn |
| Mar 31, 2024 | 330.04 Mn |
| Dec 31, 2023 | 379.50 Mn |
| Sep 30, 2023 | 423.34 Mn |
| Jun 30, 2023 | 451.63 Mn |
| Mar 31, 2023 | 686.21 Mn |
| Dec 31, 2022 | 705.89 Mn |
| Sep 30, 2022 | 749.89 Mn |
| Jun 30, 2022 | 760.15 Mn |
| Mar 31, 2022 | 763.67 Mn |
| Dec 31, 2021 | 453.60 Mn |
| Sep 30, 2021 | 723.26 Mn |
| Jun 30, 2021 | 717.08 Mn |